Drug Approval | December 23, 2025
FDA go-ahead to Roche’s one-minute follicular lymphoma therapy
Full approval will depend on verification of clinical benefit in a confirmatory trial
Full approval will depend on verification of clinical benefit in a confirmatory trial
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Several technologies for hemoglobinopathies are being transferred to commercial partners
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Subscribe To Our Newsletter & Stay Updated
